Phase II multicenter study of oblimersen sodium, a Bcl‐2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B‐cell non‐Hodgkin lymphoma
暂无分享,去创建一个
B. Leber | P. Mclaughlin | A. Younes | L. Kwak | L. Fayad | Mitchell R. Smith | Adriana López | F. Hagemeister | B. Pro | Alma M Rodriguez | J. Zwiebel | J. Romaguera | F. Samaniego